[go: up one dir, main page]

BR9808013A - Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors - Google Patents

Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors

Info

Publication number
BR9808013A
BR9808013A BR9808013-0A BR9808013A BR9808013A BR 9808013 A BR9808013 A BR 9808013A BR 9808013 A BR9808013 A BR 9808013A BR 9808013 A BR9808013 A BR 9808013A
Authority
BR
Brazil
Prior art keywords
combination therapy
reductase inhibitors
benzothiepines
bile acid
acid transport
Prior art date
Application number
BR9808013-0A
Other languages
Portuguese (pt)
Inventor
David B Reitz
Len F Lee
Jinglin J Li
Horng-Chih Huang
Samuel J Tremont
Raymond E Miller
Shyamal C Baneriee
Robert E Manning
Kevin C Glenn
Bradley T Keller
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9808013A publication Critical patent/BR9808013A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>TERAPIA DE COMBINAçãO EMPREGANDO BENZOTIEPINAS DE INIBIçãO DE TRANSPORTE DE áCIDO BILIAR "ILEAL" E INIBIDORES DE REDUTASE DE HMG CO-A"<D>. São providos novos benzotiepinas, derivados e seus análogos; composições farmacêuticas contendo eles; e métodos de uso destes compostos e composições em medicina, particularmente na profilaxia e no tratamento de condições hiperlipidêmicas tais como aquelas associadas a ateroesclerose ou hipercolesterolemia, em mamíferos. Também são providas composições e métodos para a terapia de combinação que emprega inibidores de transporte de ácido biliar "ileal" e inibidores de redutase de HMG Co-A para o tratamento de condições hiperlipidêmicas.Invention Patent: <B> COMBINATION THERAPY USING "ILEAL" BILIARY ACID TRANSPORT INHIBITION BENZOTIEPINS AND HMG CO-A "REDUCTASE INHIBITORS <D>. New benzothiepines, derivatives and their analogues are provided; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. Compositions and methods for combination therapy employing transport inhibitors are also provided. "ileal" bile acid and HMG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions.

BR9808013-0A 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors BR9808013A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
BR9808013A true BR9808013A (en) 2001-09-25

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808013-0A BR9808013A (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors

Country Status (16)

Country Link
EP (1) EP0971744A2 (en)
JP (1) JP2002500628A (en)
CN (1) CN1255864A (en)
AU (1) AU730024C (en)
BG (1) BG103793A (en)
BR (1) BR9808013A (en)
CA (1) CA2283575A1 (en)
HU (1) HUP0002395A3 (en)
IL (1) IL131872A0 (en)
MX (1) MXPA99008417A (en)
NO (1) NO994390L (en)
NZ (1) NZ337830A (en)
PL (1) PL336415A1 (en)
RU (1) RU2247579C2 (en)
SK (1) SK125099A3 (en)
WO (1) WO1998040375A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
ATE242007T1 (en) 1998-12-23 2003-06-15 Searle Llc COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (en) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (en) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment of hyperlipidemia
RU2004121898A (en) 2001-12-19 2006-01-20 Атеродженикс, Инк. (Us) CHALKONE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF DISEASES
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465885A4 (en) 2002-01-17 2005-04-27 Pharmacia Corp Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004020421A1 (en) * 2002-08-28 2004-03-11 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (en) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 New Benzothiazepines and Benzothiene Compounds
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112013010157B1 (en) 2010-11-04 2020-02-04 Albireo Ab ibat inhibitors, their uses, and pharmaceutical composition and combinations
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112014010223B8 (en) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc use of a composition comprising bile acid recycling inhibitors and pediatric dosage form
BR112015023646A2 (en) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc Recycling bile acid inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
KR20220082931A (en) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 Solid preparation, and method for preventing or reducing discoloration thereof
EP3197459B1 (en) * 2014-09-28 2025-02-12 Huahui Health Ltd. Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750944C2 (en) 2016-02-09 2021-07-06 Альбирео Аб Oral cholestyramine composition and application thereof
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
CA3073986A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
PT3810581T (en) 2018-06-20 2025-03-05 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AU2020218908B2 (en) 2019-02-06 2025-01-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
BR112021015799A2 (en) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Methods to enhance growth in pediatric patients with cholestatic liver disease
MX2022006731A (en) 2019-12-04 2022-06-09 Albireo Ab BENZOTI(DI)AZEPINE COMPOUNDS AND THEIR USE AS MODULATORS OF BILE ACID.
TWI867107B (en) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
TWI877263B (en) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 Benzothiadiazepine compounds and their use as bile acid modulators
AR120674A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID
HUE065571T2 (en) 2019-12-04 2024-06-28 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2972045T3 (en) 2019-12-04 2024-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (en) * 2020-11-23 2022-10-14 郑州大学 Preparation method of a cholesterol oxidase-modified hybrid metal-organic framework tumor-targeting nanoformulation
KR20230117393A (en) 2020-12-04 2023-08-08 알비레오 에이비 Benzothia(di)azepine compounds and their use as bile acid regulators
TW202313579A (en) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
CN119343140A (en) 2022-06-09 2025-01-21 阿尔比里奥公司 Treating Hepatitis
TW202423921A (en) * 2022-08-22 2024-06-16 美商安塔製藥公司 Fused heterobicyclic antiviral agents
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK0549967T3 (en) * 1991-12-20 1996-07-22 Hoechst Ag Polymers and oligomers of bile acid derivatives, processes for their preparation and their use as pharmaceuticals
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
CN1255864A (en) 2000-06-07
MXPA99008417A (en) 2005-02-03
NO994390L (en) 1999-11-04
JP2002500628A (en) 2002-01-08
NO994390D0 (en) 1999-09-10
PL336415A1 (en) 2000-06-19
NZ337830A (en) 2001-07-27
BG103793A (en) 2000-07-31
SK125099A3 (en) 2001-02-12
HUP0002395A3 (en) 2002-12-28
CA2283575A1 (en) 1998-09-17
EP0971744A2 (en) 2000-01-19
WO1998040375A3 (en) 1998-12-03
RU2247579C2 (en) 2005-03-10
IL131872A0 (en) 2001-03-19
AU730024C (en) 2004-08-05
AU6440898A (en) 1998-09-29
WO1998040375A2 (en) 1998-09-17
HUP0002395A2 (en) 2001-05-28
AU730024B2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
BR9808013A (en) Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors
BR9916484A (en) Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents in cardiovascular indications
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
BR9916565A (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
EP0896533A4 (en) Pentafluorobenzenesulfonamides and analogs
BR9916567A (en) Combinations of inhibitors of ileal dabile acid transport and nicotinic acid derivatives for cardiovascular indications
BR9713400A (en) Processes and compounds to inhibit beta-amyloid peptide release and / or its synthesis.
ATE303378T1 (en) BENZOTHIEPINES ACTING AS INHIBITORS OF ILEUMGALLIC ACID TRANSPORT AND TAUROCHOLATE ABSORPTION
BR9711805A (en) Compounds and methods for providing pharmacologically active preparations and use
NO20092860L (en) 2, 6 dioxopiperidine and pharmaceutical compositions containing them
BR9916486A (en) Combinations of bile acid transport inhibitors in the ileum and cholesterol ester transfer protein inhibitors for cardiovascular indications
BR9901491A (en) 7-hetero-bicycles [2.2.1] - heptanes.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
BR9913855A (en) 1-2-3-4- tetrahydroquinolines substituted in position 2 and substituted in position 4 with amino as cetp inhibitors
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
BG102836A (en) New benzazepine derivatives, medicamentous forms containing them, and their application for the preparation of medicaments
BR9813468A (en) Angiogenesis triazine inhibitors
DE69811062D1 (en) POLYAROMATIC ANTIVIRAL COMPOSITIONS
IL142066A0 (en) Arylsulfonanilide urea derivatives and pharmaceutical compositions containing the same
AP9701041A0 (en) Pyridylpyrrole compounds.
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
BR0004535A (en) Compounds, and, use of them.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.